Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
MGI PHARMA INC (MOGN)
|
Add to portfolio |
|
|
|
| Price: |
$33.28
| | Metrics |
| OS: |
78.1
|
M
| |
-4
|
% ROE
|
| Market cap: |
$2.6
|
B
| |
-1
|
% ROIC
|
|
Net cash:
|
$79
|
M
| |
$1.01
|
per share
|
|
EV:
|
$2.52
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($475.0)
|
k
| |
|
|
|
EBIT
|
($475.0)
|
k
| |
|
|
| EPS |
($111.59)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| Revenues | 342.8 | 279.4 | 195.7 | 49.4 | 28.2 | 33.0 |
| Revenue growth | 22.7% | 42.8% | 296.2% | 75.1% | -14.4% | |
| Cost of goods sold | 123.4 | 97.4 | 60.8 | 8.2 | 4.4 | 3.6 |
| Gross profit | 219.4 | 182.0 | 134.8 | 41.2 | 23.8 | 29.3 |
| Gross margin | 64.0% | 65.1% | 68.9% | 83.5% | 84.3% | 89.0% |
| Selling, general and administrative | 148.4 | 89.0 | 73.8 | 50.4 | 28.8 | 28.5 |
| Research and development | 100.1 | 70.9 | 62.6 | 50.1 | 32.2 | 36.1 |
| EBITA | -29.1 | 22.1 | -1.6 | -59.3 | -37.3 | -35.2 |
| EBITA margin | -8.5% | 7.9% | -0.8% | -120.1% | -132.1% | -106.9% |
| Amortization of intangibles | | | | | | 1.2 |
| EBIT | -29.1 | 22.1 | -1.6 | -59.3 | -37.3 | -36.4 |
| EBIT margin | -8.5% | 7.9% | -0.8% | -120.1% | -132.1% | -110.5% |
| Pre-tax income | -39.3 | -132.0 | -85.4 | -61.9 | -36.1 | -34.8 |
| Income taxes | 0.8 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% |
| Net income | -40.2 | -132.4 | -85.7 | -61.9 | -36.1 | -34.8 |
| Net margin | -11.7% | -47.4% | -43.8% | -125.4% | -127.9% | -105.7% |
| |
| Diluted EPS | ($512.19) | ($1,810.78) | ($1,226.42) | ($1.11) | ($0.72) | ($1.74) |
| Shares outstanding (diluted) | 0.1 | 0.1 | 0.1 | 55.6 | 50.2 | 20.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|